Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

Dyne Therapeutics is a clinical-stage neuromuscular disease company that utilizes its proprietary FORCE platform to develop targeted therapeutics for genetically driven neuromuscular diseases. Their lead programs have shown promising clinical data, with potential for differentiation in the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. Despite some residual risks, as with any biotechnology company, we believe Dyne has strong potential for success and could become a leader in the rare genetic muscle disease space.

Bears say

Dyne Therapeutics is currently facing several fundamental challenges that may impact the success and valuation of its FORCE platform, including the potential for safety issues and a residual clinical risk in its programs. Additionally, the recent setback from NVS in a similar therapy casts doubt on DYN's ability to meet its primary endpoint in upcoming trials. These factors, along with a potential lack of statistically significant results and a reliance on biopsies and unadjusted data, lead to our negative outlook on the company's stock.

Dyne Therapeutics (DYN) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 10 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.